Filing Flows › Taysha Gene Therapies (TSHA) › Q4 2025
Taysha Gene Therapies (TSHA) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 19, 2026
Taysha Gene Therapies (TSHA) reported revenue of $5.5M for the fourth quarter 2025 (Q4 2025), +171% from a year earlier. Operating margin was -516.0%, net loss $27.9M (507.8% of revenue).
Taysha Gene Therapies, Q4 2025: revenue $5.5M (+171% year over year), operating margin -516.0%, net loss $27.9M, operating cash flow −$26.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.5M | — | +171% |
| Operating profit | −$28.3M | — | — |
| Net earnings | −$27.9M | — | — |
| Operating cash flow | −$26.7M | — | — |
What changed
Revenue was $5.5M in Q4 2025, up 171% year over year.
Operating costs exceeded revenue by $28.3M, an operating margin of -516.0%. Total costs grew 54% against revenue growth of 171%. The fastest-growing cost line was Research & development (+63%). The quarter ended with a net loss of $27.9M.
Operating cash flow was −$26.7M. Non-cash charges added back $299K of depreciation and $3.5M of share-based compensation. Working capital and other items used $2.7M. Capital expenditures of $250K exceeded it, leaving free cash flow of −$27.0M.
Questions
What was Taysha Gene Therapies' revenue in the fourth quarter 2025?
Taysha Gene Therapies (TSHA) reported revenue of $5.5M for the fourth quarter 2025 (Q4 2025), +171% from a year earlier.
Was Taysha Gene Therapies profitable in the fourth quarter 2025?
Operating loss was $28.3M (-516.0% of revenue) and net loss $27.9M.